Additional file 1 of The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Creators: name: Tseng, Ping-Tao
name: Zeng, Bing-Yan
name: Hsu, Chih-Wei
name: Hung, Chao-Ming
name: Carvalho, Andre F.
name: Stubbs, Brendon
name: Chen, Yen-Wen
name: Chen, Tien-Yu
name: Lei, Wei-Te
name: Chen, Jiann-Jy
name: Su, Kuan-Pin
name: Shiue, Yow-Ling
name: Liang, Chih-Sung
Publisher: name: figshare
Year: 2025
Subjects: subject: Medicine
subject: Neuroscience
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Science Policy

description: Supplementary Material 1: Fig. S1. (A) Network structure of primary outcome: subgroup analysis of Alzheimer’s disease events; (B) Network structure of primary outcome: subgroup analysis of dementia of Lewy body events; (C) Network structure of primary outcome: subgroup analysis of multiple sclerosis events; (D) Network structure of primary outcome: subgroup analysis of amyotrophic lateral sclerosis events; (E) Network structure of safety profile: drop-out rate. Fig. S2. (A) Forest plot of primary outcome: subgroup analysis of Alzheimer’s disease events; (B) Forest plot of primary outcome: subgroup analysis of dementia of Lewy body events; (C) Forest plot of primary outcome: subgroup analysis of multiple sclerosis events; (D) Forest plot of primary outcome: subgroup analysis of amyotrophic lateral sclerosis events; (E) Forest plot of safety profile: drop-out rate. Fig. S3. Summary plot of ranking of primary outcome (overall events of neurodegenerative diseases). Fig. S4. Individual study result of primary outcome: overall events of neurodegenerative diseases. Fig. S5. Bayesian-based forest plot of primary outcome: overall events of neurodegenerative diseases. Fig. S6. (A) Bayesian-based Litmus Rank-O-Gram rank plot of primary outcome: overall events of neurodegenerative diseases; (B) Bayesian-based radial surface under the cumulative ranking of primary outcome: overall events of neurodegenerative diseases. Fig. S7. (A) Bayesian-based residual deviance NMA/UME model of primary outcome: overall events of neurodegenerative diseases; (B) Bayesian-based per-arm residual deviance of primary outcome: overall events of neurodegenerative diseases; (C) Bayesian-based leverage plot of primary outcome: overall events of neurodegenerative diseases. Fig. S8. Detailed risk of bias in each study. Tab. S1. (A) PRISMA 2020 checklist of the current network meta-analysis; (B) PRISMA 2020 abstract checklist of the current network meta-analysis. Tab. S2. Keyword used in each database and search results. Tab. S3. Excluded studies and reason. Tab. S4. Characteristics of the included studies. Tab. S5. (A) League table of primary outcome: subgroup of Alzheimer’s disease events; (B) League table of primary outcome: subgroup of dementia of Lewy body events; (C) League table of primary outcome: subgroup of multiple sclerosis events; (D) League table of primary outcome: subgroup of amyotrophic lateral sclerosis events; (E) League table of safety profile: drop-out rate. Tab. S6. Surface under the cumulative ranking of primary outcome: overall events of neurodegenerative diseases. Tab. S7. (A) Inconsistency within the primary outcome: overall events of neurodegenerative diseases; (B) Inconsistency within the primary outcome: subgroup of Parkinson’s disease events; (C) Inconsistency within the primary outcome: subgroup of Alzheimer’s disease events; (D) Inconsistency within the primary outcome: subgroup of dementia of Lewy body events; (E) Inconsistency within the primary outcome: subgroup of multiple sclerosis events; (F) Inconsistency within the primary outcome: subgroup of amyotrophic lateral sclerosis events; (G) Inconsistency within the safety profile: drop-out rate. Legends to Combined Additional files [7–13, 16, 19–23, 26–28, 31–41, 47–65, 74–176, 187].